Skip to main content
. 2016 Aug 27;7(41):66835–66850. doi: 10.18632/oncotarget.11652

Figure 5. Effects of ARF deficiency on immune and angiogenic pathways.

Figure 5

mRNA expression of (A) M2 markers (Arg- 1, Fizz-1, Ym-1, MRC1/CD206, MGL-2), (B) cytokines and chemokines (IL-10, TGF-β, CCL-17, CCL-22, CCL-5), (C) angiogenic factors (VEGFR2, VE-cadherin, VCAM-1, PECAM-1/CD31, ICAM-1) and (D) inhibitors of angiogenesis (TIMP-3) were evaluated by quantitative PCR in tumor xenografts from WT and ARF−/− mice. In all cases, mRNA induction levels were normalized to 36B4 mRNA expression. Data are means of each group ± S.D. (n = 6). *P < 0.05, **P < 0.01 and ***P < 0.001. (E) Western blot analysis of the protein levels of TIMP-3 in tumors from WT or ARF−/− mice. Numbers (1, 2, 3) indicate different animals of the same group. Band intensity of Western blots was analyzed by densitometry, normalized to β-actin levels and represented as the mean ± SD of the fold change from control condition (n = 3). *p < 0.05 with respect to WT mice.